Hypermethylated gene promoters can serve as blood-based DNA methylation biomarkers signaling occult metastatic disease or recurrence (for example, CDH1 or RARB methylation in circulating tumor DNA) [40,41,42]. The gene discussed is CDH1; the disease is neoplasm.